TECHBio-Techne
$72.79+20% 1Y
$72.79
$43.2252 weeks$72.79
Latest close: a new 52-week highNov 6, 2026what changed →
The business
How TECH's business earns
Bio-Techne earns 9.4% on the capital it employs against an estimated 9.0% cost of capital.
9.4%
Return on invested capital · cost of capital 9.0% · 0.44 points above the estimated cost of capital
- Operating margin
- 20%
Operating margin · Biotechnology median −62% · 12 months to Sep 30, 2026
- Cash conversion
- 1.85×
Cash conversion · 3.12× a year ago · operating cash flow divided by operating profit after tax
- Share count, year on year
- +1.0%
Share count, year on year · within 1% of a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2021 | 25% |
| FY2022 | 27% |
| FY2023 | 26% |
| FY2024 | 18% |
| FY2025 | 8.4% |
| FY2026 | 21% |
Details›
- Gross margin12 months to Sep 30, 2026
- 66%
- Operating margin12 months to Sep 30, 2026
- 20%
- Net margin12 months to Sep 30, 2026
- 14%
- Free cash flow margin
- 25%
- R&D as % of revenue
- 7.9%
- Revenue, trailing twelve months
- $1.23B
- Free cash flow, trailing twelve months
- $308M
- Net income, trailing twelve months
- $172M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 9.4%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screensStocks with more cash than debt
Biotechnology
The closest names by size in the same industry